About
Sansimeon is a life science tools company building an automated, integrated sample-to-answer single-cell sequencing platform that combines standardized sample preparation with scalable sequencing to generate large single-cell multi-omics datasets for drug discovery, translational research and ML; supported by NIH NIGMS SBIR grants.
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Sansimeon, Inc.
Sansimeon is a life science tools company building an automated, integrated sample-to-answer single-cell sequencing platform that combines standardized sample preparation with scalable sequencing to generate large single-cell multi-omics datasets for drug discovery, translational research and ML; supported by NIH NIGMS SBIR grants.
—
United States
BusinessLatest roundTotal raisedDate- Portal Biotechnologies
Silicon micropore mechanical-poration intracellular delivery hardware (Gateway, Millibooster, Galaxy-i, etc.) and consumables for pharma companies, academic hospitals and biotech labs, with a DARPA contract, replacing viral vectors and lipid nanoparticles for cell engineering, gene editing, RNA therapy and AI drug discovery research
$5M
$5M - LogicFlo AI
Builds AI assistants that automate research tasks for life sciences teams
Seed · $3M · 2025-07
$3M - ExaCare AI
AI automation tools for admissions and clinical decisions at post-acute care facilities
Series A · $30M · 2025-10
$30M
China
BusinessLatest roundTotal raisedDate- ATLATL Innovation Center
R&D infrastructure and incubation for early-stage biopharma: shared labs, resident scientists and project management, GMP process optimization, preclinical pharmacology and toxicology, plus an AI drug screening module, for biopharma startups, university and institute spinout teams and multinational pharma
— - Coherence Biotech Co. Ltd.
Lab automation: the Keystone™ benchtop all-in-one system combines culturing, intervention and microscopy imaging into uninterrupted multi-day cell/organoid experiments and uses AI vision to identify, count and track cells, generating structured experimental data for AI drug discovery
— - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M
Europe
BusinessLatest roundTotal raisedDate- Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M - IMU Biosciences
Multi-omics and machine learning analysis of blood samples to quantify immune system activity and generate immune profiles for clinical research and treatment decisions
Series A · $60M · 2026-06
$60M - Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M
Other / unspecified
BusinessLatest roundTotal raisedDate- Resonata Health
Matching engine connecting patients to clinical trials and approved therapies, serving patients, clinical research sites and biopharma companies
— - Reliant AI
Uses generative AI to help biopharma companies organize and analyze data for clinical trials or scientific publications
Seed · $11M · 2024-08
$11M - Sarborg
AI agents that help pharmaceutical companies optimize drug repurposing and clinical trial decisions
Seed · $10M · 2025-08
$10M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.